hCRLF2

Nomenclature

C57BL/6Smoc-Crlf2tm1(hCRLF2)Smoc

Cat. NO.

NM-HU-210028

Strain State

Embryo cryopreservation

Export PDF

Gene Summary

Gene Symbol
Crlf2

Synonyms

CRLM2; Ly114; Tpte2; Tslpr

NCBI ID

57914

MGI ID

1889506

Ensembl ID

ENSMUSG00000033467

Pubmed

Crlf2

Human Ortholog

CRLF2

Model Description

The endogenous mice Crlf2 gene was completely or partially replaced by human CRLF2 gene via ESC targeting.
Research Application：inmmue therapy；drug screening

Validation Data

image.png

Fig.1 Detection of hCRLF2 expression in the bone marrow of hCRLF2 knockin mice. (male, 13-week-old)

Abbr.  WT, wild type; HO, homozygous.

image.png

Fig.2 Detection of hCRLF2 expression in the blood of hCRLF2 knockin mice. (male, 13-week-old)

Abbr.  WT, wild type; HO, homozygous.

image.png

Fig.3 Detection of hCRLF2 expression in the spleen of hCRLF2 knockin mice. (male, 13-week-old)

Abbr.  WT, wild type; HO, homozygous.

image.png

Fig.4 Detection of mCRLF2 expression in the bone marrow of hCRLF2 knockin mice. (male, 13-week-old)

Abbr.  WT, wild type; HO, homozygous.

image.png

Fig.5 Detection of mCRLF2 expression in the blood of hCRLF2 knockin mice. (male, 13-week-old)

Abbr.  WT, wild type; HO, homozygous.

image.png

Fig.6 Detection of mCRLF2 expression in the spleen of hCRLF2 knockin mice. (male, 13-week-old)

Abbr.  WT, wild type; HO, homozygous.

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more